Company intelligence / Profile preview

iScience Interventional

Menlo Park, California, United Statesiscienceinterventional.com ↗

Ownership: Private
Development stage: Commercial

Overview

Developed the first microcatheter and high-resolution imaging systems enabling site-specific ocular therapies. Canaloplasty with the iTRACK 250 catheter demonstrated effectiveness comparable to surgery for lowering intraocular pressure in glaucoma patients while reducing medication needs and offering a favorable benefit/risk profile. The company was recognized as a pioneer in minimally invasive interventional ophthalmology procedures.

Therapeutic areas: Ophthalmology
Modalities: DeviceMicrocatheter-based therapyImaging system (for site-specific ocular drug delivery)
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on iScience Interventional.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iScience Interventional.

Explore the full profile